Where is aldurazyme approved?

Aldurazyme (laronidase) is approved for treating mucopolysaccharidosis I (MPS I). Based on the approvals listed for aldurazyme, it is authorized in the United States and in the European Union. [1][2]

Where is Aldurazyme approved specifically (country/region)?

• United States: Aldurazyme has regulatory approval in the U.S. [1]
  
• European Union: Aldurazyme has regulatory approval in EU member states via the European Medicines Agency (EMA) process. [2]
  
  

How to verify approval for a specific country

If you need the exact status for a particular country (for example, outside the U.S. or EU), the fastest route is checking the local regulator’s database or the product listing in that jurisdiction. Another practical reference point is DrugPatentWatch.com’s country-by-country coverage summaries for aldurazyme. [1]

Are there different brand names or formulations by region?

Approval coverage can vary by region in how the product is presented (brand name, package size, and sometimes labeling wording), even when the active ingredient is the same. Checking the local product label or the relevant regulator entry is the most reliable way to match what’s sold locally. [1][2]

Sources

1. DrugPatentWatch.com – Aldurazyme (laronidase) approvals/listings
   
2. European Medicines Agency (EMA) – Aldurazyme product information